Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group.

Details

Ressource 1Download: serval:BIB_06A919A7FBA1.P001 (142.67 [Ko])
State: Public
Version: author
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_06A919A7FBA1
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group.
Journal
Annals of Oncology
Author(s)
Italiano A., Penel N., Robin Y.M., Bui B., Le Cesne A., Piperno-Neumann S., Tubiana-Hulin M., Bompas E., Chevreau C., Isambert N., Leyvraz S., du Chatelard P.P., Thyss A., Coindre J.M., Blay J.Y.
ISSN
1569-8041
Publication state
Published
Issued date
2009
Peer-reviewed
Oui
Volume
20
Number
3
Pages
425-430
Language
english
Abstract
BACKGROUND: There are only scarce data about the benefit of adjunctive chemotherapy in patients with localized synovial sarcoma (SS). PATIENTS AND METHODS: Data from 237 SS patients recorded in the database of the French Sarcoma Group were retrospectively analyzed. The respective impact of radiotherapy, neo-adjuvant chemotherapy and adjuvant chemotherapy on overall survival (OS), local recurrence-free survival (LRFS) and distant recurrence-free survival (DRFS) were assessed after adjustment to prognostic factors. RESULTS: The median follow-up was 58 months (range 1-321). Adjuvant, neo-adjuvant chemotherapy and postoperative radiotherapy were administered in 112, 45 and 181 cases, respectively. In all, 59% of patients treated with chemotherapy received an ifosfamide-containing regimen. The 5-year OS, LRFS and DRFS rates were 64.0%, 70% and 57%, respectively. On multivariate analysis, age >35 years old, grade 3 and not-R0 margins were highly significant independent predictors of worse OS. After adjustment to prognostic factors, radiotherapy significantly improved LRFS but not DRFS or OS. Neither neo-adjuvant nor adjuvant chemotherapy had significant impact on OS, LRFS or DRFS. CONCLUSION: As for other high-grade soft-tissue sarcomas, well-planned wide surgical excision with adjuvant radiotherapy remains the cornerstone of treatment for SS. Neo-adjuvant or adjuvant chemotherapy should not be delivered outside a clinical trial setting.
Pubmed
Web of science
Open Access
Yes
Create date
17/03/2009 15:19
Last modification date
25/09/2019 6:08
Usage data